Novartis | pharmaphorum

Skip to main content

Tuesday 10 February 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Novartis

Views & Analysis

ASCO 2018 imagery

ASCO 2018 Preview – what to expect from this year’s conferen...

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.

News

Aimovig

Novartis/Amgen's migraine drug hits market at lower than exp...

The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and at a lower than expected list price of $6,900.

News

Novartis HQ

Novartis lawyer steps down after Trump scandal

Former CEO Jimenez breaks silence over scandal

News

gilenya

FDA backs Novartis' Gilenya in paediatric MS

First disease modifying therapy approved in paediatric MS

News

Novartis HQ

Novartis paid $1.2m to Trump lawyer for policy insights

Special counsel also contacted pharma over Trump's Russian links

News

Novartis' groundbreaking Kymriah

Novartis matches Gilead on price in new CAR-T use

Novartis won't offer 'money back' scheme because of delayed effect

Load more results

Editor's Picks

White House's TrumpRx platform has arrived

Hims & Hers copies Novo Nordisk's new Wegovy pill

Lilly says 2026 looks good, as sales rocket in Q4

Fears US drug pricing deal will weigh heavy on the NHS

FDA launches pilot programme to boost US manufacturing

R&D

Interview at JPM26 with Laurent Audaly

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company